Évaluation de l’insulinosécretion et de l’insulinosensibilité

Kahn, 2003, The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes, Diabetologia, 46, 3, 10.1007/s00125-002-1009-0 Scheen, 2001, Le concept d’insulinosensibilité, Diabetes Metab, 27, 193 Scheen, 2000, Insulin resistance versus insulin deficiency: which one comes first? The old question revisited, 101 Scheen, 1995, Glucose metabolism in obese subjects: lessons from OGTT, IVGTT, and clamp studies, Int J Obesity, 19, S14 American Diabetes Association, 1998, Consensus Development Conference on insulin resistance, Diabetes Care, 21, 310, 10.2337/diacare.21.2.310 Krentz, 2005, Oral antidiabetic agents. Current role in type 2 diabetes mellitus, Drugs, 65, 385, 10.2165/00003495-200565030-00005 Nathan, 2006, Diabetologia, 49, 1711, 10.1007/s00125-006-0316-2 Scheen, 1998, Oral antidiabetic agents: a guide to selection, Drugs, 55, 225, 10.2165/00003495-199855020-00004 Polonsky, 1986, Current approaches to measurement of insulin secretion, Diabetes Metab Rev, 2, 315, 10.1002/dmr.5610020306 Hovorka, 1994, How to measure insulin secretion, Diabetes Metab Rev, 10, 91, 10.1002/dmr.5610100204 Scheen, 1995, Comment évaluer la sécrétion insulinique en pratique ?, Diabetes Metab, 21, 458 Vague, 2001, Rationale and methods for the estimation of insulin secretion in a given patient. From research to clinical practice, Diabetes, 51, S240 Scheen, 2005, Evaluation de l’insulinosécrétion, 98 Wallace, 2004, Use and abuse of HOMA modeling, Diabetes Care, 27, 1487, 10.2337/diacare.27.6.1487 Polonsky, 1986, The limitations to and valid use of Cpeptide as a marker of the secretion of insulin, Diabetes, 35, 379, 10.2337/diab.35.4.379 Del Prato, 2001, The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus, Diabetes Metab Res Rev, 17, 164, 10.1002/dmrr.198 Scheen, 2004, Pathophysiology of insulin secretion, Ann Endocrinol (Paris), 65, 29, 10.1016/S0003-4266(04)95627-2 Scheen, 1996, Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test. Methodological aspects and clinical applications, Diabete Metab, 22, 397 Byrne, 1995, Insulin secretion and clearance during lowdose graded glucose infusion, Am J Physiol, 268, E21 Bergman, 1989, Towards physiological understanding of glucose tolerance, Minimal-model approach. Diabetes, 38, 1512 Bergman, 2002, Accurate assessment of β-cell function, Diabetes, 51, S212, 10.2337/diabetes.51.2007.S212 DeFronzo, 1979, Glucose clamp technique: a method for quantifying insulin secretion and resistance, Am J Physiol, 232, E214 Mitrakou, 1992, Simultaneous assessment of insulin secretion and insulin sensitivity using a hyperglycemic clamp, J Clin Endocrinol Metab, 75, 379 Stumvoll, 2000, Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity, Diabetes Care, 23, 295, 10.2337/diacare.23.3.295 Luyckx, 2003, L’hyperglycémie provoquée par voie orale. Etude de la sécrétion, de la clairance et de l’action de l’insuline, et du rétrocontrôle par les hormones de la contre-régulation, Immunoanal Biol Spéc, 18, 185 Mari, 2002, Meal and oral glucose tests for assessment of β cell function: modelling analysis in normal subjects, Am J Physiol Endocrinol Metab, 283, E1159, 10.1152/ajpendo.00093.2002 Fritsche, 2000, A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility, Eur J Clin Invest, 30, 411, 10.1046/j.1365-2362.2000.00649.x Scheen, 1996, Glucagon-induced plasma C-peptide response in diabetic patients. Influence of body weight and relationship to insulin requirement, Diab Metab, 22, 455 Kjems, 2000, Validation of methods for measurement of insulin secretion in humans in vivo, Diabetes, 49, 580, 10.2337/diabetes.49.4.580 Bergman, 1985, Assessment of insulin sensitivity in vivo, Endocr Rev, 6, 45, 10.1210/edrv-6-1-45 Scheen, 1994, How to measure insulin action in vivo?, Diabetes Metab Rev, 10, 151, 10.1002/dmr.5610100206 Raynaud, 1998, Evaluation in vivo de la sensibilité à l’insuline et applications cliniques, Ann Biol Clin, 56, 407 Scheen, 1999, Comment apprécier chez l’homme l’action de l’insuline en recherche et en pratique, Ann Endocrinol (Paris), 60, 179 Rabasa-Lhoret, 2001, Mesurer l’insulinosensibilité en pratique clinique, Diabetes Metab, 27, 201 Wallace, 2002, The assessment of insulin resistance in man, Diabet Med, 19, 527, 10.1046/j.1464-5491.2002.00745.x Scheen, 2004, L’insulinorésistance : comment l’évaluer en pratique clinique ?, Métabolismes Hormones Diabètes Nutrition, 8, 21 Scheen, 2005, Les critères de l’insulinorésistance en clinique, 19 Katz, 2000, Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans, J Clin Endocrinol Metab, 85, 2402, 10.1210/jcem.85.7.6661 Mather, 2001, Repeatability characteristics of simple indices of insulin resistance: implications for research applications, J Clin Endocrinol Metab, 86, 5457, 10.1210/jcem.86.11.7880 Albareda, 2000, Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test, Diabetologia, 43, 1507, 10.1007/s001250051561 Hansen, 2007, The BIGTT test. A novel test for simultaneous measurement of pancreatic β-cell function, insulin sensitivity, and glucose tolerance, Diabetes Care, 30, 257, 10.2337/dc06-1240 Ferrannini, 2004, Beta-cell function and its relation to insulin action in man: a critical appraisal, Diabetologia, 47, 943, 10.1007/s00125-004-1381-z Abdul-Ghani, 2006, Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose, Diabetes Care, 29, 1130, 10.2337/dc05-2179 Ferrannini, 2005, β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis, J Clin Endocrinol Metab, 90, 493, 10.1210/jc.2004-1133 Abdul-Ghani, 2006, Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study, Diabetes, 55, 1430, 10.2337/db05-1200